The CEO's statement suggests that Wegovy may become a more integral and long-term part of obesity treatment regimens. This could lead to increased and more stable revenues for Novo Nordisk as patients stay on the medication for longer periods. The positive sentiment from the company's leadership is likely to be viewed favorably by investors, potentially leading to a short-term increase in stock price.